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One of the main effects of the endocannabinoid system
in the brain is stress adaptation with presynaptic endo-
cannabinoid receptor 1 (CB1 receptors) playing a major
role. In the present study, we investigated whether
the effect of the CB1 receptor coding CNR1 gene on
migraine and its symptoms is conditional on life stress.
In a cross-sectional European population (n= 2426),
recruited from Manchester and Budapest, we used the
ID-Migraine questionnaire for migraine screening, the
Life Threatening Experiences questionnaire to measure
recent negative life events (RLE), and covered the CNR1
gene with 11 SNPs. The main genetic effects and the
CNR1×RLE interaction with age and sex as covariates
were tested. None of the SNPs showed main genetic
effects on possible migraine or its symptoms, but 5
SNPs showed nominally signiﬁcant interaction with
RLE on headache with nausea using logistic regression
models. The effect of rs806366 remained signiﬁcant
after correction for multiple testing and replicated in
the subpopulations. This effect was independent from
depression- and anxiety-related phenotypes. In addition,
a Bayesian systems-based analysis demonstrated that
in the development of headache with nausea all SNPs
were more relevant with higher a posteriori probability
in those who experienced recent life stress. In summary,
the CNR1 gene in interaction with life stress increased
the risk of headache with nausea suggesting a spe-
ciﬁc pathological mechanism to develop migraine, and
indicating that a subgroup of migraine patients, who
suffer from life stress triggered migraine with frequent
nausea, may beneﬁt from therapies that increase the
endocannabinoid tone.
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Migraine is a complex multifactorial neurologic disorder, in
which genetic factors explain about 46% of the risk with the
remaining 54% of the variability related to environmental fac-
tors (Mulder et al. 2003). Recent genome wide association
studies (GWAS) have successfully identiﬁed several genetic
susceptibility loci for migraine (Anttila et al. 2013; Gormley
et al. 2016) but much less is known of which genetic vari-
ants operate in the presence of a given environmental effect
(Eising et al. 2013b).
One of the main environmental risk factor for migraine
is psychosocial stress (Sauro & Becker 2009), and it has
been demonstrated that migraine patients show maladap-
tive stress responses (Borsook et al. 2012; Lipton et al.
2014). The endocannabinoid system plays a key role in
modulation of stress response (Hill et al. 2010; McLaughlin
et al. 2014). Its two main mediators are anandamide (AEA)
and 2-arachidonoylglycerol (2-AG) that are synthesized on
demand in the postsynaptic cells and act as retrograde neuro-
transmitters on GABAergic and glutamatergic neurons to bal-
ance inhibitory and excitatory neural activity. In the brain the
primary target of endocannabinoids is the endocannabinoid
receptor 1 (CB1 receptor), which is predominantly expressed
in cortical and limbic areas and is responsible for the regula-
tion of stress response and emotional behaviour (McLaughlin
et al. 2014).
Activation of the CB1 receptors enhances the activity
of serotonergic (5HT) and noradrenergic (NA) neurons
in the brainstem (McLaughlin et al. 2014) and, through
negative feedback inhibition, controls the activity of
hypothalamic–pituitary–adrenal (HPA) axis (Hill et al. 2010).
Thus lack or decreased CB1 signalling results in chronic
stress-like state (Lazary et al. 2011). More importantly, it
has been demonstrated that during chronic stress the
endocannabinoid signalling changes gradually leading to
stress habituation (Patel & Hillard 2008), which is impaired in
migraine patients (Afra et al. 2000).
Indeed, it has been previously proposed that migraine
is related to endocannabinoid deﬁciency (Russo 2004),
although whether it is the cause or the consequence of
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migraine has not been understood yet. In human studies, the
metabolism of endocannabinoids is increased in migraineurs
(Cupini et al. 2006) resulting in decreased endocannabinoid
tone (Sarchielli et al. 2007; Van der Schueren et al. 2012).
In addition, animal studies showed that AEA was able to
diminish the activation of the trigeminovascular system in
nitroglycerin-induced migraine models (Akerman et al. 2004;
Greco et al. 2010; Nagy-Grocz et al. 2015) through a CB1
receptor mediated mechanism (Akerman et al. 2013).
Indeed, our previous genetic association studies showed
that genetic variants in the CB1 receptor coding CNR1 gene
were associated with neuroticism (Juhasz et al. 2009a), a
personality trait which predisposes to perceive life events
as stressful and which is a risk factor for migraine (Ligth-
art & Boomsma 2012). In addition, CNR1 genetic variants in
interaction with recent negative life events (RLE) increased
the risk of depression (Juhasz et al. 2009a), and in interac-
tion with the serotonin transporter functional polymorphism
(5HTTLPR) exerted anxiogenic effects (Lazary et al. 2009,
2011). Regarding migraine, we demonstrated that a CNR1
haplotype increased the risk of migraine headaches (Juhasz
et al. 2009b). However, recent migraine GWAS studies could
not identify risk genetic variants within the endocannabinoid
system (Anttila et al. 2013; Gormley et al. 2016). Although
accumulating evidence suggests that impaired CB1 signalling
is associated with chronic stress-related hyperalgesia (Jen-
nings et al. 2015; Lomazzo et al. 2015; Rea et al. 2014), the
relationship between CNR1 gene and migraine has not been
investigated in interaction with life stressors.
Thus, in the present study we tested the hypothesis
that the CNR1 gene in interaction with life stressors is an
important risk factor for migraine type headache, in a Euro-
pean cohort recruited from Budapest and Manchester. Fur-
thermore, we hypothesized that the modulatory effect of
life stress - CNR1 gene interaction is different for speciﬁc
migraine related symptoms.
Materials and methods
Subjects
Participants aged between 18 and 60 years fromGreater Manchester,
UK and Budapest, Hungary have been recruited through general prac-
tices and advertisements. The studies were part of NewMood (New
Molecules in mood Disorders, 2004–2009), an EU funded research
programme into pathomechanism of depression and related condi-
tions. Both studies were approved by local Ethics Committees (Scien-
tiﬁc and Research Ethics Committee of the Medical Research Coun-
cil, Budapest, Hungary, ad.225/KO/2005.; ad.323-60/2005-1018EKU
and ad.226/KO/2005.; ad.323-61/2005-1018 EKU; North Manchester
Local Research Ethics Committee, Manchester, UK REC reference
number: 05/Q1406/26) and were carried out in accordance with the
Declaration of Helsinki. All participants provided written informed
consent to the study. In the present research, we included partic-
ipants who were European white origin, completed the question-
naires and consented to DNA. Details of the recruitment strategies
and response rate were published earlier (Juhasz et al. 2009a; Lazary
et al. 2009).
Questionnaires
Brief standard questionnaires, English and Hungarian versions
respectively, were used for the study. The background questionnaire
collected information about socio-demographic data, personal and
family psychiatric history. Sex, age, ethnicity, reported migraine and
reported lifetime depression data were derived from this validated
questionnaire (Juhasz et al. 2011).
The ID-migraine questionnaire was used to collect information
about headaches and especially migraine type headache symptoms
in the past 3 months (Lipton et al. 2003). The ID-Migraine is a
validated screening tool for migraine, which includes 3 items of
the main migraine symptoms: nausea, photophobia and disability. In
the present study we assigned possible migraine to patients who
answered YES to 2 or 3 migraine symptom questions as they have
93% probability of having migraine based on the IHS diagnostic
criteria for migraine (Lipton et al. 2003). In addition, we investigated
the genetic effect on the 3 reported symptoms separately.
The RLE score was based on the validated Life Threatening Expe-
riences questionnaire (Brugha et al. 1985) and we calculated the sum
of negative life events in the last year for the analysis.
To measure neuroticism the Big Five Inventory (BFI-44) (John &
Srivastava 1999) was applied. Current (last week) anxiety symptoms
and depressive symptoms were measured by the relevant subscales
of the Brief Symptom Inventory (BSI) (anxiety subscale for anxiety,
and depression plus additive subscales for depression; (Derogatis
1993). For these variables continuous weighted dimension scores
(sum of item scores divided by the number of items completed) were
calculated for the analysis.
Genotyping
Genomic DNA was extracted from buccal mucosa cells (Juhasz
et al. 2009a). After extraction of DNA all samples were normal-
ized and genotyped using the Sequenom® MassARRAY Technology
(Sequenom®, San Diego, CA, USA, www.sequenom.com). Genotyp-
ing was performed under the ISO 9001:2000 requirements and was
blinded for the phenotypic data.
To investigate the effect of the CNR1 gene we selected possibly
functional single nucleotide polymorphisms (SNPs) from previous lit-
erature and haplotype tag SNPs (htSNPs) to cover the whole gene.
Genetic data were extracted from the International HapMap project
(http://hapmap.ncbi.nlm.nih.gov/, Phase I. June 2005, CEPH popu-
lation and AFD_EUR_18-MAY-2004 panel). Gabriel method imple-
mented in the HaploView software package was used to identify
htSNPs with minimum pairwise correlation r2 =0.8 (Gabriel et al.
2002a). The list and minor allele frequencies of the selected SNPs
can be seen in Table 1.
Statistical analysis
To calculate Hardy-Weinberg equilibrium P values, to run logistic
regression analysis with additive genetic models, and to compute
haplotypes PLINK v1.07 (http://pngu.mgh.harvard.edu/˜purcell/plink/)
analysis programme was used. First, statistical analysis for the main
effect of the CNR1 SNPs and the CNR1 SNPs×RLE interactions
on possible migraine and migraine-related symptoms were car-
ried out in the total sample, according to a recent guideline (Dick
et al. 2015). Pairwise deletion was used to handle missing data.
To adjust P values for the multiple testing false discovery rate q
values were calculated and were accepted at level of 5% (Q value,
http://www.bioconductor.org/packages/release/bioc/html/qvalue.
html). To handle possible ancestral differences, ethnicity was deter-
mined by the self-reported data derived from the Background
questionnaire (see Questionnaires) and subjects with European
white origin were included in the analysis. In addition, possible
ancestral differences according to study sites were tested by includ-
ing this factor (namely, Budapest vs. Manchester) into the post
hoc tests. Thus we tested the main ﬁnding in these subgroups
separately, and also ran a post hoc test by including study site into
the analysis.
In addition, haplotypeswere computed for the nominally signiﬁcant
SNPs in haploblock 1 applying the expectation maximization (EM)
algorithm. The effects of the computed haplotypes were similarly
tested in the total sample as the SNPs, also as a post hoc test. Age
and sex were covariates in all analyses.
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Table 1: Details of the investigated populations
A. Phenotypic description Total population Manchester Budapest
Demographics
Participant number (n) 2426 1375 1051
Female (n, %) 1690 (70%) 958 (70%) 732 (70%)
Age (mean ± SEM) 32.9 (± 0.22) 34.04 (± 0.28) 31.2 (± 0.34)
Migraine and headache
Reported migraine (n, %) 144 (6%) 104 (8%) 40 (4%)
ID-possible migraine (n, %) 668 (28%) 430 (31%) 238 (23%)
ID nausea (n, %) 710 (29%) 454 (33%) 256 (24%)
ID photophobia (n, %) 688 (28%) 433 (32%) 255 (24%)
ID disability (n, %) 673 (28%) 422 (31%) 251 (24%)
Stresses
Recent negative life events (mean ± SEM) 1.22 (± 0.03) 1.32 (± 0.04) 1.08 (± 0.04)
Recent life event categories (n, %)
No or mild 1619 (67%) 880 (64%) 739 (70%)
Moderate 451 (19%) 258 (19%) 193 (19%)
Severe 352 (14%) 237 (17%) 115 (11%)
Psychiatric measures
Reported lifetime depression (n, %) 989 (41%) 770 (56%) 219 (21%)
BFI neuroticism (mean ± SEM) 3.12 (± 0.02) 3.36 (± 0.03) 2.81 (± 0.03)
BSI current depression score (mean ± SEM) 0.85 (± 0.02) 1.07 (± 0.03) 0.55 (± 0.02)
BSI current anxiety score (mean ± SEM) 0.87 (± 0.02) 1.02 (± 0.03) 0.69 (± 0.02)
B. Genetic data
Minor allele frequencies (MAF)∗
rs2180619 (G/A) 39.6% 37.8% 42.2%
rs806379 (T/A) 47.4% 49.5% 44.7%
rs1535255 (G/T) 17.3% 18.7% 15.4%
rs2023239 (C/T) 17.6% 19.1% 15.5%
rs806369 (T/C) 30.0% 27.9% 32.8%
rs1049353 (A/G) 25.9% 28.3% 22.7%
rs4707436 (A/G) 26.1% 28.5% 22.9%
rs12720071 (G/A) 8.8% 8.3% 9.6%
rs806368 (C/T) 21.3% 20.0% 23.2%
rs806366 (T/C) 48.4% 49.7% 46.9%
rs7766029 (T/C) 48.1% 46.3% 50.4%
(A) Shows the phenotypic data, (B) summarises the genetic variables.
BFI, Big Five Inventory (30); BSI, Brief Symptom Inventory (31); ID, data derived from the ID-Migraine questionnaire (28); SEM, standard
error of mean.
∗All SNPs are in Hardy-Weinberg equilibrium with an average callrate of 95%.
To further explore the effects of CNR1 SNPs in subpopulations
deﬁned by the recent life event categories (no or mild=0–1, moder-
ate=2, severe=3 or more) systems-based Bayesian relevance anal-
ysis was carried out (Antal et al. 2006, 2014; Hullam et al. 2012)
to determine the strong relevance of predictors (11 CNR1 SNPs,
age and sex) with respect to headache with nausea. This method
applies Bayesian model averaging, both at structural and parametric
levels, which provides a coherent multivariate solution for the multi-
ple hypothesis problem. For detailed method, see Antal et al. (2014)
and Juhasz et al. (2014, 2015).
Additional statistical analyses were performed with SPSS 21.0 for
Windows (IBM). All statistical testing adopted two-tailed P =0.05
threshold. For display purposes, in all three RLE severity categories,
we calculated positive likelihood ratios (LR+) for signiﬁcant geno-
types and haplotypes by dividing the genotype/haplotype frequen-
cies in possible migraine cases/symptom carriers by those in control
subjects/non-carriers, as previously described (Juhasz et al. 2009b).
Quanto 1.2 version (http://biostats.usc.edu/Quanto.html/) was
employed to calculate the power of the recruited populations.
Assuming a case–control design (3 controls/case) and an additive
genetic model with a minor allele frequency between 10% and 50%
in our study (n=2426) we have 45–84% power to detect genetic
main effects and 65–95% power to detect a gene× environment
interaction (P =0.05 two-tailed) that is associated with 1.2 odds ratio
for a disease.
Results
Detailed description of the included study population can
be found in Table 1. Two-thirds of the recruited study
population was female and about 40% reported lifetime
depression.
Despite the fact that only 6% of the subjects reported
migraine as a long-standing medical condition in the
total study population, about one-third of the subjects
had migraine-related symptoms when they experienced
headache in the last 3 months. Based on our data in
this study the ID migraine questionnaire compared to the
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Total population LD D’ Total population LD R2
Figure 1: LD block structure of the total population. Linkage analysis showed two main haploblocks (haploblock 1: rs806366,
rs806368, rs12720071, rs4707436, rs1049353, rs806369 and haploblock 2: rs2023239, rs1535255, rs806379; while rs7766029 at the
3′ end and rs2180619 at the 5′ end were not in linkage with these haploblocks.
reported migraine had 85% sensitivity and 76% speciﬁcity
to identify possible migraine, which is in a comparable range
with the original validation study (Lipton et al. 2003).
CNR1 gene
All of the investigated SNPs were in Hardy-Weinberg equi-
librium, both in the total population and in the separate
populations according to study sites of Budapest and
Manchester, respectively. Linkage analysis in HaploView
(Barrett et al. 2005; Gabriel et al. 2002b) showed two
main haploblocks (haploblock 1: rs806366, rs806368,
rs12720071, rs4707436, rs1049353, rs806369, and hap-
loblock 2: rs2023239, rs1535255, rs806379; while rs7766029
at the 3′ end and rs2180619 at the 5′ end were not in linkage
with these haploblocks. This genetic structure was similar
in the Budapest and Manchester sample and agrees with
the LD pattern of the European white populations. (For LD
block structure of the total population see Fig. 1, and of the
investigated subpopulations see Fig. S1.)
Main effect of RLEs on headache
Using logistic regression model, as we expected, with
increasing number of RLE the odds of having possible
migraine or migraine related symptoms were increased [pos-
sible migraine: Odds Ratio (OR)=1.32 (95% CI 1.23–1.41)
P < 0.001; nausea: OR= 1.24 (95% CI 1.16–1.33) P <0.001;
photophobia: OR=1.24 (95% CI 1.16–1.33) P < 0.001; dis-
ability: OR=1.28 (95% CI 1.19–1.37) P <0.001; Fig. 2]. This
effect remained signiﬁcant when lifetime depression, current
depression and anxiety score, and neuroticismwere included
in the regression model [possible migraine: OR=1.17
Figure 2: Effect of life stresses on headache. RLEs (recent
negative life events) experienced in the last year increased the
positive likelihood ratio of having possible migraine or migraine
related symptoms with headache, deﬁned by the ID-Migraine
screening questionnaire.
(95% CI 1.08–1.26) P < 0.001; nausea: OR=1.10 (95%
CI 1.02–1.18) P =0.014; photophobia: OR= 1.15 (95% CI
1.07–1.23) P < 0.001; disability: OR=1.16 (95% CI 1.08–1.25)
P <0.001].
Main effect of CNR1 gene on headache
None of the investigated SNPs showed signiﬁcant main
genetic effect on possible migraine or migraine related symp-
toms using logistic regression models with age and sex as
co-variants.
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Table 2: Statistical results of interaction effect between RLE and CNR1 gene haplotype tag SNPs in the total study population
Possible migraine Headache with nausea Headache with photophobia Headache with disability
SNP A1 OR L95 U95 P OR L95 U95 P OR L95 U95 P OR L95 U95 P
1 rs2180619 G 1.006 0.908 1.115 0.904 0.922 0.834 1.021 0.118 1.000 0.904 1.106 0.999 1.021 0.923 1.130 0.687
2 rs806379 T 0.969 0.877 1.071 0.537 1.012 0.917 1.117 0.811 0.910 0.825 1.004 0.061 1.007 0.912 1.112 0.893
3 rs1535255 G 0.919 0.808 1.044 0.195 0.939 0.828 1.065 0.326 0.963 0.850 1.093 0.562 0.966 0.851 1.097 0.594
4 rs2023239 C 0.931 0.816 1.062 0.287 0.935 0.822 1.063 0.302 0.985 0.867 1.120 0.820 1.000 0.878 1.138 0.994
5 rs806369 T 1.085 0.967 1.217 0.166 1.123 1.002 1.259 0.045 1.090 0.974 1.221 0.134 1.086 0.970 1.217 0.154
6 rs1049353 A 0.885 0.789 0.993 0.037 0.846 0.755 0.948 0.004 0.965 0.863 1.079 0.531 0.915 0.817 1.024 0.123
7 rs4707436 A 0.892 0.796 1.001 0.051 0.860 0.767 0.963 0.009 0.981 0.877 1.097 0.737 0.928 0.829 1.039 0.196
8 rs12720071 G 1.003 0.833 1.209 0.974 0.980 0.816 1.178 0.832 0.944 0.786 1.132 0.531 0.933 0.780 1.115 0.447
9 rs806368 C 1.010 0.896 1.139 0.873 0.943 0.838 1.061 0.327 0.985 0.876 1.107 0.797 0.974 0.865 1.096 0.661
10 rs806366 T 0.884 0.791 0.987 0.028 0.819 0.733 0.916 0.0005∗ 0.959 0.862 1.066 0.438 0.896 0.804 0.999 0.048
11 rs7766029 T 1.111 1.001 1.232 0.047 1.114 1.006 1.234 0.038 1.079 0.976 1.194 0.139 1.103 0.996 1.222 0.060
Possible migraine: 2 or 3 migraine related symptoms measured by the ID-Migraine screening questionnaire.
Bold, nominally signiﬁcant effects; italic, trend effects; L95-U95, 95% conﬁdence interval; OR, odds ratio; P, signiﬁcance.
∗Remained signiﬁcant after false discovery rate correction of multiple testing.
Figure 3: rs806366 effect on headache with nausea. The
interaction effect of recent negative life events (RLE) and the
rs806366 within the CNR1 gene on headache with nausea in the
total population. Number of cases in the no or mild RLE group:
CC=361, CT=684, TT=315. Number of cases in the moderate
RLE group: CC= 103, CT=183, TT= 95. Number of cases in the
severe RLE groups: CC=74, CT= 147, TT=69.
CNR1×RLE interaction on headache
Nominally signiﬁcant interaction effects were identiﬁed
between rs1049353, rs806366, rs7766029 and RLE on pos-
sible migraine, between rs806369, rs1049353, rs4707436,
rs806366, rs7766029 and RLE on headache with nausea,
and between rs806366 and RLE on headache with disability
(Table 2). Taking into account the number of tests we carried
out (4 phenotypes, genetic main effect, gene×environment
interactions, 11 SNPs) after false discovery rate correction
for multiple testing the interaction effect of rs806366 and
RLE on headache with nausea remained signiﬁcant (FDR
q =0.040). The minor T allele decreased the risk of having
headache with nausea with the increasing number of RLE
(Fig. 3).
Post hoc tests of CNR1×RLE interaction
on headache with nausea
Investigating the CNR1×RLE interaction on headache with
nausea separately according to study sites, 8 out of 11
SNPs showed the same direction of effect in both popula-
tions and the effect of rs806366×RLE was replicated in the
Budapest and Manchester samples at nominal signiﬁcance
level (Table 3).
In the total population, the rs806366×RLE interaction
effect remained signiﬁcant after controlling for the effects of
the study site, neuroticism, lifetime depression and current
depression and anxiety scores (Table 3).
To demonstrate the cumulative effect of the signiﬁcant
SNPs in haploblock 1 (rs806366, rs4707436, rs1049353,
rs806369) in the total population we computed haplotypes
and tested the CNR1×RLE interaction effects on headache
with nausea (for haplotype frequency and results see Table
S1, Supporting Information and Fig. 2). The most frequent
TGGC haplotype (frequency 30.8%) was a signiﬁcant risk
variant [OR=1.20 (95% CI 1.06–1.36) P = 0.005] whereas
the complementary CAAT haplotype (frequency 26.5%)
showed signiﬁcant protective effect [OR=0.84 (95% CI
0.75–0.95) P =0.006; Fig. 4]. Other frequent haplotypes
(frequency>5%) had no signiﬁcant interaction effect on
headache with nausea.
Bayesian relevance of CNR1 SNPs on headache
with nausea in different RLE categories
Using a Bayesianmodel averaging approach overmodels con-
sisting of all SNPs plus age and sex, an a posteriori probability
of strong relevance was calculated for each predictor. Results
indicated that all CNR1 SNPs had higher a posteriori proba-
bility of strong relevance in subgroups with either moderate
or severe RLE (moderate=2, severe=3 or more serious life
events in the last year) compared to no or mild RLE (no or
mild= 0–1 serious life events in the last year) (Fig. 5 and
Appendix S1). The a posteriori probability of strong relevance
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Table 3: Post hoc analysis of CNR1×RLE interaction on headache with nausea in the separate study populations, and in the total
population after controlling for study sites, neuroticism, lifetime depression and current depression and anxiety scores
Budapest Manchester
Total population corrected for study
site and depression related variables
SNP A1 OR L95 U95 P OR L95 U95 P OR L95 U95 P
1 rs2180619 G 1.055 0.879 1.266 0.564 0.870 0.768 0.985 0.028 0.931 0.836 1.036 0.189
2 rs806379 T 0.905 0.759 1.080 0.268 1.083 0.959 1.224 0.199 1.033 0.930 1.146 0.547
3 rs1535255 G 0.977 0.791 1.208 0.830 0.923 0.788 1.081 0.322 0.935 0.820 1.067 0.319
4 rs2023239 C 0.937 0.757 1.160 0.550 0.939 0.798 1.105 0.449 0.925 0.809 1.057 0.253
5 rs806369 T 1.173 0.962 1.430 0.115 1.087 0.942 1.254 0.252 1.128 0.998 1.275 0.054
6 rs1049353 A 0.875 0.711 1.077 0.209 0.834 0.726 0.959 0.011 0.840 0.744 0.948 0.005
7 rs4707436 A 0.869 0.706 1.068 0.181 0.856 0.745 0.983 0.028 0.854 0.757 0.964 0.010
8 rs12720071 G 1.176 0.853 1.621 0.324 0.910 0.721 1.150 0.431 0.964 0.797 1.164 0.700
9 rs806368 C 0.953 0.783 1.160 0.630 0.943 0.811 1.095 0.440 0.941 0.831 1.065 0.335
10 rs806366 T 0.818 0.677 0.988 0.037 0.829 0.720 0.955 0.009 0.814 0.722 0.917 0.0007
11 rs7766029 T 1.026 0.848 1.240 0.792 1.149 1.013 1.303 0.030 1.104 0.990 1.232 0.076
Bold, nominally signiﬁcant effects; italic, trend effects; L95-U95, 95% conﬁdence interval; OR, odds ratio; P, signiﬁcance.
Figure 4: CNR1 haplotype effect on headache with nausea.
Signiﬁcant CNR1 haplotype× recent negative life events (RLE)
interaction effects on headache with nausea in the total popu-
lation. Number of cases in the no or mild RLE group: TGGC carri-
ers= 733, CAAT carriers= 620. Number of cases in the moderate
RLE group: TGGC carriers=186, CAAT carriers=177. Number of
cases in the severe RLE groups: TGGC carriers= 152, CAAT car-
riers=144.
was highest for rs806366 (Pr= 0.8) in the severe RLE sub-
population, giving a similar result to the frequentist analysis.
This suggests that in 80% of all models the rs806366 was an
important factor to determine headache with nausea.
Discussion
Our results show that the CNR1 gene in interaction with
life stresses increases the risk of headache with nausea,
suggesting a potential speciﬁc pathological mechanism in
the development of migraine. This ﬁnding emphasises that
possible migraine, as a screening questionnaire outcome,
is not directly associated with the CNR1 gene, which is
supported by recent GWAS studies (Anttila et al. 2013).
However, (1) the CNR1 gene exerts a signiﬁcant effect on
headache with nausea rather than possible migraine itself,
and (2) the CNR1 gene effect on headache with nausea is
conditional on the presence of stressors that might serve
as migraine triggers. This latter observation is supported
by previous studies, which conﬁrmed that endocannabinoid
signalling has a fundamental role in stress adaptation (Hill
et al. 2010).
A recent large meta-analysis of GWAS studies (Anttila
et al. 2013) identiﬁed several susceptible genetic loci for
migraine from which only one (TRPM8, encoding the tran-
sient receptor potential melastatin 8, which is a cold and
menthol-activated ion channel in sensory neurons) has a
direct role in pain sensation. The other genetic variants are
predominantly expressed in the brain, mainly exert their
effects through synaptic and neuronal regulation (Anttila et al.
2013; Eising et al. 2013a) and thus may contribute to the neu-
ronal hyperexcitability of the migraine brain. In addition, it
has been demonstrated that these genetic variants, with the
exception of TRPM8, show different and unique association
patterns with additional migraine features, such as nausea,
photophobia or aggravation by physical activity, which sug-
gests that genetic variants play a divergent pathophysiologi-
cal role in the development of migraine (Chasman et al. 2014;
Zameel Cader 2013), similar to our ﬁnding.
The endocannabinoid system, acting through the CNR1
coded CB1 receptor, is another key player in synaptic plas-
ticity that has modulatory effects on trigeminovascular acti-
vation (Akerman et al. 2004, 2013; Nagy-Grocz et al. 2015),
pain processing (Morena et al. 2016) and regulation of nausea
and vomiting (Parker et al. 2011; Sharkey et al. 2014) draw-
ing attention to its potential role in the pathophysiology of
migraine.
Our results do not support the hypothesis that in humans
genetic variations of the CNR1 gene are directly associated
with migraine type headache through the effect of endo-
cannabinoid system on trigeminovascular activation. This is
because we have not seen any signiﬁcant main effects of
6 Genes, Brain and Behavior (2016)
CNR1, stress and headache
Figure 5: Relevance of CNR1
SNPs on headache with nausea.
A posteriori probability of strong
relevance of CNR1 SNPs on
headache with nausea according
to the RLE (recent negative life
events) exposure.
SNPs on possible migraine headache. Indeed, CB1 recep-
tors are more abundantly expressed in the prefrontal cortical
areas compared to the brainstem (McLaughlin et al. 2014). In
our previous smaller study, we found direct effects of CNR1
gene on migraine only when using extreme trait combina-
tions (0 symptoms vs. 3 symptoms on ID-Migraine question-
naire) and haplotype analysis of the CNR1 gene. Even in this
case, in the extended sample (including those who has only 1
or 2 symptoms) the distribution of association patterns with
other migraine related symptoms were uneven (Juhasz et al.
2009b) suggesting that this gene has a selective pathophys-
iological role.
The endocannabinoid system plays an important regula-
tory role in pain processing at multiple levels of this pathway.
The activation of the CB1 receptors have analgesic effects
at the peripheral sensory afferents, in the dorsal horn of the
spinal cord, the periaqueductal grey (PAG) and the brainstem
(Woodhams et al. 2015). In addition, endocannabinoids are
indispensable in the development of acute stress induced
analgesia (Morena et al. 2016), and the downregulation of
endocannabinoid signalling is an important mechanism in the
development of chronic stress induced hyperalgesia (Jen-
nings et al. 2015; Lomazzo et al. 2015; Rea et al. 2014). How-
ever, more and more evidence suggests that endocannabi-
noids mainly inﬂuence the affective component of pain, in
which amygdala activity has a pivotal role, compared to the
sensory aspects (Lee et al. 2013). As such, the strength of
life stress×CNR1 gene interaction on headache with nausea
would be expected to decrease after controlling for depres-
sion and anxiety related phenotypes, but this was not the
case. Thus, our ﬁndings suggest that a distinctivemechanism
related to stress induced headache with nausea is primar-
ily responsible for the effect of CNR1 gene in migraine type
headache in humans.
Nausea and/or vomiting is a characteristic feature of
migraine headache, which has been reported by 70–90% of
migraine patients (Lipton et al. 2001). The presence of nausea
and its intensity correlates signiﬁcantly with migraine pain
severity (Kelman & Tanis 2006). In addition, frequent nausea
occurs in about 50% of migraine sufferers where headache
is accompanied by nausea more than half of the time, which
predicts more disability (Lipton et al. 2013), worse quality of
life, and transition to chronic migraine (Reed et al. 2015). Fur-
thermore, a major problemwith nausea is that it can interfere
with willingness to take and ingest oral migraine medication
causing ineffective pain control (Lipton et al. 2013).
Accumulating evidence supports cannabis and endo-
cannabinoids supressing emesis and nausea through the
CB1 receptor (Parker et al. 2011; Sharkey et al. 2014). In
animal models, cannabinoid derivatives have a distinctive
effect compared to other available antiemetic drugs in being
able to suppress not only vomiting but also anticipatory and
delayed nausea, probably via the inhibitory effect of CB1
receptors on serotonin release in the insular cortex (Parker
et al. 2015); this is a possible mechanism in humans as well.
The neural regulator of emesis is integrated at the dorsal
vagal complex, which receives peripheral (gut), vestibular, and
cerebral inputs and initiates motor response characteristic
for vomiting (Parker et al. 2011; Sharkey et al. 2014). Never-
theless, the neuronal control of nausea is poorly understood
but is clearly distinctive from the emesis control. A recent
human functional magnetic resonance imaging (fMRI) study
suggested that sustained nausea activates an extensive net-
work of limbic, interoceptive and cognitive brain areas includ-
ing the insular cortex and the anterior cingulate (Napadow
et al. 2013). Correlation between the activity of the insular
cortex and midcingulate predicted the development of strong
nausea (Napadow et al. 2013). In addition, a recent PET study
demonstrated that nausea as a premonitory symptom during
nitroglycerin-inducedmigraine is centrally driven by activation
of the PAG and rostral dorsal medulla or regions that control
their activity (Maniyar et al. 2014).
The headache escalating effect of nausea can be experi-
mentally demonstrated in migraine patients during motion
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sickness by applying a painful stimuli on the face (Drummond
& Granston 2004). This observation suggests that the dorso-
vagal complex and the trigeminovascular complex mutually
relay information to each other which leads to a vicious cir-
cle increasing both symptoms (Cuomo-Granston & Drum-
mond 2010; Drummond & Granston 2004). It is interesting to
note, that migraineurs are more susceptible to motion sick-
ness than controls probably due to the ineffective top-down
control on relevant brainstem areas in response to exces-
sive or stressful sensory inputs (Cuomo-Granston & Drum-
mond 2010). Regarding motion sickness, it has been demon-
strated that those who respond with acute motion sick-
ness to parabola ﬂight have signiﬁcantly higher stress scores
accompanied by increased salivary cortisol concentration,
lower whole blood endocannabinoid levels and decreased
CB1 mRNA leukocyte expression compared to those with no
motion sickness (Chouker et al. 2010).
Limitations
The main advantage of our study is that the systematic inves-
tigation of genetic main effect and stress interaction on dif-
ferent migraine related symptoms allowed us to delineate a
speciﬁc pathomechanism, whichmay contribute to the devel-
opment of migraine in a susceptible subgroup of patients.
However, the study has some limitations. Although we man-
aged to replicate our ﬁndings in two European populations,
independent replications will be necessary to conﬁrm our
results. Our study had a cross-sectional design, therefore the
causative role of life stressors and the temporal relationship
between stress and headache could not be investigated. Fur-
thermore, we used a short screening questionnaire to deter-
mine the probability of migraine headache and to identify
migraine related symptoms without proper medical diagno-
sis. Nevertheless, this is a usual method in large population
based studies and previous epidemiologic and GWAS studies
suggest that this method provides trustworthy results (Anttila
et al. 2013).
Finally, although we covered the whole CNR1 gene with
haplotype tag SNPs to determine its function in migraine,
the endocannabinoid system is a very complex network
of synthetizing and metabolizing enzymes, receptors and
transporters with high potential to adaptive changes. For
example, genetic variants in the gene of fatty acid amide
hydrolase (FAAH) enzyme, which metabolizes AEA, have
been associated not only with pain sensitivity (Cajanus et al.
2016) but with mood symptoms elicited by early life stress
(Lazary et al. 2016), probably through neurodevelopmental
effects. Indeed, the endocannabinoid system is responsible
to regulate divergent physiological processes frommetabolic
routes through regulation of emotional behaviour to pain
modulation, reﬂected by its broad expression throughout the
brain and other parts of the body, making it challenging to
speciﬁcally target it by therapeutic interventions. Although, a
promising approach is to increase the endocannabinoid tone
by inhibiting the FAAH enzyme that showed antinociceptive
(Greco et al. 2015) and antiemetic (Parker et al. 2015) effects
in animal models, serious treatment related adverse events
in a recent human study suggest that tissue and/or receptor
speciﬁc cannabinoids are warranted (Kaur et al. 2016).
Conclusions
In conclusion, our results suggest that genetic variations in
the CNR1 gene increases the risk of developing headache
with nausea in life stress exposed subjects most likely
through an impaired endocannabinoid system driven
top-down cortical control on important brainstem areas.
Based on these results a subgroup of migraine patients,
who have frequent nausea associated with migraine attacks
triggered by moderate or severe life stress, may beneﬁt from
therapies that increase the endocannabinoid tone.
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